AICAR peptide is an AMPK-activating research compound studied for metabolism and endurance. Learn how it works, what the evidence shows, and its legal status.
AICAR is a research compound that activates AMPK, the enzyme cells use to sense energy status, and it is not actually a peptide despite the name used in many online listings. It is a nucleoside analog, which is a small molecule that mimics part of a nucleotide, and it is not approved by the FDA for human use. Almost all of the evidence behind AICAR comes from cell cultures and rodents rather than controlled human trials.
Is AICAR Actually a Peptide?
No. The full chemical name is 5-aminoimidazole-4-carboxamide ribonucleotide, and it behaves like a nucleotide-based molecule rather than a chain of amino acids.
Real peptides are short strings of amino acids, usually somewhere between two and fifty residues long. AICAR is a single small molecule that cells convert into ZMP, an AMP mimic. The "peptide" label appears to come from the research chemical market, where nearly every vial is marketed with the same vocabulary.
That distinction matters for buyers. Peptides and nucleoside analogs are studied differently, handled differently, and dosed differently, so assuming AICAR is a peptide can create the wrong expectations about how it works and what risks it carries.
How AICAR Works in the Body
Once inside a cell, AICAR is phosphorylated into ZMP. Rising ZMP levels imitate a shortage of cellular energy, and AMPK responds by switching on catabolic pathways while switching off energy-storing ones.
In laboratory models, AMPK activation from AICAR has been linked to:
- Increased fatty acid oxidation in muscle and liver tissue
- Greater glucose uptake into skeletal muscle
- Reduced fat synthesis and storage
- Improved insulin sensitivity in obese rodent models
These effects are metabolic, not hormonal. AICAR does not act on androgen receptors and does not build muscle the way anabolic compounds do. Sustained AMPK activation may actually interfere with muscle protein synthesis, which is one reason many strength athletes avoid it.
What the Research Shows
The best-known AICAR study appeared in the journal Cell in 2008, when researchers combined AICAR with GW1516 and reported a large increase in running endurance in mice. That paper helped create the "exercise in a pill" headline that still follows the compound today.
Results in mice have not been reproduced at scale in humans. AICAR was tested in people under the name acadesine, mostly in cardiac surgery trials during the 1990s and 2000s; a large trial in high-risk coronary artery bypass patients did not show a clear benefit.
There is no published human dosing protocol for performance or fat loss. Advice circulating online is usually derived from rodent studies scaled by body weight, which is not a reliable method for setting human doses.
AICAR vs. Other Research Compounds
AICAR is often compared with GW1516 and with repair-focused peptides, even though these compounds work through completely different pathways.
| Compound | Chemical class | Main mechanism | Human evidence | US regulatory status |
|---|---|---|---|---|
| AICAR | Nucleoside analog (not a peptide) | Activates AMPK through ZMP | Limited; cardiac surgery trials under the name acadesine showed no clear benefit | Not FDA-approved; banned in sport |
| GW1516 (cardarine) | Synthetic PPAR-delta agonist | Alters fat and glucose gene expression | None for human use | Not FDA-approved; FDA has warned consumers |
| BPC-157 | Synthetic peptide fragment | Tissue-repair signaling in animal models | No approved human trials | Not FDA-approved; sold as research chemical only |
Researchers studying the bpc-157 peptide for inflammation and AICAR frequently read the same forums, but the two compounds share no mechanism, no dosage range, and no safety profile.
Safety, Legal Status, and Anti-Doping Rules
AICAR is not approved by the FDA for any human use, and it is not a lawful dietary supplement ingredient in the United States. Products labeled "AICAR peptide" are typically sold for research use only, which is a legal disclaimer rather than a safety guarantee.
The World Anti-Doping Agency added AICAR to its prohibited list in 2009 as an AMPK activator, and it remains banned in and out of competition for athletes in most sanctioned sports.
Because human safety data are thin, the side effect profile is largely unknown. Concerns raised in the literature include:
- Interference with muscle growth and recovery from prolonged AMPK activation
- Blood sugar effects, including possible additive interactions with metformin and other diabetes drugs
- Injection-site infections and contamination risks with unregulated vials
- Unknown long-term effects on the heart, immune system, and liver
Questions to Ask Before Considering AICAR
- Is the product approved for human use? For AICAR, the answer is no.
- What human data support the dose being suggested? Usually none.
- Could it interact with prescription medications you already take? Ask a pharmacist or physician.
- Is the substance banned in your sport or workplace? AICAR is banned by WADA.
Anyone weighing a research compound for a health goal should talk with a licensed healthcare professional first, especially if they take prescription medication or have a heart, liver, or metabolic condition.
Why AICAR Gets Grouped With Peptide Products
Growth in the research chemical market has pushed a wide range of compounds into the same online storefronts, and product pages often blur the categories.
That overlap shows up in peptide drug development as well: some metabolic peptides are genuinely in clinical trials, while AICAR's human data remain limited to older hospital-based research. The result is a marketplace where a nucleoside analog can sit beside a synthetic peptide with no real scientific connection between them.
Consumers searching for a peptide for weight loss often land on AICAR listings because of the endurance and fat-oxidation headlines. Likewise, people browsing natural peptide supplements may assume the same quality standards apply to every vial on the page, and they do not.
The practical takeaway is that category labels are unreliable in this space. Peptide science moves quickly, but marketing language moves faster, and "AICAR peptide" is a name that says more about sales copy than about chemistry.
Frequently Asked Questions
Is AICAR peptide legal in the United States?
AICAR is not FDA-approved for human use and is not a permitted dietary supplement ingredient in the United States. Products sold online are typically labeled "for research use only," which is a disclaimer rather than proof of safety or legality for consumption. The World Anti-Doping Agency also bans AICAR for athletes in sanctioned sports.
Is AICAR a peptide or a steroid?
It is neither. AICAR is a nucleoside analog, a small molecule that cells convert into ZMP, which then activates the enzyme AMPK. It is not a chain of amino acids like a peptide, and it does not act on hormone receptors the way anabolic steroids do.
What does AICAR do in the body?
In animal and cell studies, AICAR activates AMPK and shifts metabolism toward fat oxidation and glucose uptake, which is why it is studied for endurance and metabolic effects. Human evidence is limited, and there is no established human dose for performance or fat loss. Because human safety data are scarce, side effects and long-term risks are largely unknown.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.